Clinical Trials

Alkaline phosphatase (ALP) blood test

Displaying 3 studies

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid Scottsdale/Phoenix, AZ

The primary objective of the study is to compare the effect of daily oral administration of elafibranor 80mg and 120 mg on change in serum alkaline phosphatase (ALP) to that of placebo in patients with PBC and inadequate response to Ursodeoxycholic acid (UDCA).
Study to Assess Safety and Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid Scottsdale/Phoenix, AZ

The purpose of this study is to assess the safety and efficacy of GKT13783 in patients with Primary Biliary Cholangitis (PBC) who are taking a stable dose of ursodeoxycholic acid (UDCA) treatment, and have persistently high levels of a liver enzyme called Alkaline Phosphatase (ALP).
Prevalence of Hypophosphatasia in Patients with Fibromyalgia at the Mayo Clinic Rochester, MN

The overall goal of this research is to identify patients in clinical practice that have unrecognized hypophosphatasia (HPP) and select appropriate candidates for therapy. The purpose of this proposal is to identify the prevalence of adults with hypophosphatasia within a previously identified fibromyalgia cohort at our institution.